Prostate Cancer

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

A new drug application for a 3-month depot formulation of leuprolide mesylate has been submitted to the FDA.

Bertram Yuh, MD, MISM, MSHCPM, discussed how single-port robotic surgery has changed treatment paradigms for patients with prostate cancer.

The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately 220 patients with prostate cancer with biochemical recurrence.

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer.

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall survival vs enzalutamide monotherapy.

The FDA has approved the WATER IV PCa trial, which will compare the safety and efficacy of Aquablation therapy to radical prostatectomy in patients with localized prostate cancer.

Savita Dandapani, MD, PhD, discussed combining radium-223 and SBRT for metastatic castration-sensitive prostate cancer.

In an interview with Targeted Oncology, Chunhui Han, PhD, discussed the use of Ga 68 PSMA-11 for the imaging of metastatic sites in patients with prostate cancer.

For Prostate Cancer Awareness Month, Jeffrey Y.C. Wong, MD, discussed the evolving field of prostate cancer treatment and how it continues to improve.

A supplemental new drug application seeking expanded indication for darolutamide combined with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer has been submitted to the FDA.

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases.

The FDA has approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to be used with olaparib, abiraterone, and prednisone or prednisolone BRCA-mutated metastatic castration-resistant prostate cancer.

In an interview, Anil Parwani, MD, PhD, discussed how artificial intelligence can be used in medical education and training, as well as its role in personalized medicine.

64Cu-SAR-bisPSMA gained FDA fast track status for advanced prostate cancer imaging.

In an interview, Benjamin H. Lowentritt, MD, FACS, compared PSA response rates between apalutamide and enzalutamide in patients with metastatic castration-sensitive prostate cancer.

TLX007-CDx, if approved by the FDA, has the potential to become a new PSMA PET imaging agent for prostate cancer.

Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.

BNT324/DB-1311 gained fast track designation from the FDA in unresectable advanced or metastatic castration-resistant prostate cancer who have progressed after standard treatments.

The FDA has granted fast track designation to 225Ac-FL-020, a promising PSMA-targeting radionuclide drug conjugate for metastatic castration-resistant prostate cancer.

The tissue-based companion diagnostic device was approved for the same therapy and indication in August 2023.

Five-year follow-up from the IMpower010 trial shows atezolizumab improves overall survival vs BSC in resected stage IB-IIIA NSCLC.

A new radioligand therapy, JNJ-6420, shows promise in treating metastatic castration-resistant prostate cancer with deep and lasting responses after just 1-2 doses.

Based on a post-hoc analysis of the ARAMIS trial, darolutamide was associated with lower rates of PSA and radiological progression vs placebo as well as improving overall survival in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide delays time to progression from mHSPC to mCRPC vs placebo while also increasing overall survival benefit.

A post-hoc analysis showed suspending enzalutamide does not impact quality of life in patients with nonmetastatic hormone-sensitive prostate cancer in the phase 3 EMBARK trial.

Apalutamide plus androgen deprivation therapy does not appear to negatively impact quality of life in patients with recurrent prostate cancer, while still improving progression-free survival.

Cabazitaxel plus abiraterone showed improved survival results for patients with previously treated metastatic castration-resistant prostate cancer.